-
公开(公告)号：US20210011022A1
公开(公告)日：2021-01-14
申请号：US16870006
申请日：2020-05-08
发明人： Xi-Tao WANG , Olufemi A. ADELAKUN , Anne C. LEWIN , Alan J. KORMAN , Mark J. SELBY , Changyu WANG , Haichun HUANG , Karla A. HENNING , Nils LONBERG , Mohan SRINIVASAN , Michelle Minhua HAN , Guodong CHEN , Richard Y. HUANG , Indrani CHAKRABORTY , Susan Chien-Szu WONG , Huiming LI
IPC分类号： G01N33/574 , G01N33/566 , C07K16/28
摘要： Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.
-
12.发明申请公开(公告)号：US20200079865A1
公开(公告)日：2020-03-12
申请号：US16578987
申请日：2019-09-23
发明人： Changyu WANG , Nils LONBERG , Alan J. KORMAN , Mark J. SELBY , Mohan SRINIVASAN , Karla HENNING , Michelle Minhua HAN , Guodong CHEN , Richard HUANG , Indrani CHAKRABORTY , Haichun HUANG , Susan WONG , Huiming LI
IPC分类号： C07K16/28 , G01N33/68 , A61K39/395 , G01N33/574
摘要： Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US20190112375A1
公开(公告)日：2019-04-18
申请号：US16228095
申请日：2018-12-20
发明人： Mark F. MAURER , Tseng-hui Timothy CHEN , Brigitte DEVAUX , Mohan SRINIVASAN , Susan H. JULIEN , Paul O. SHEPPARD , Daniel F. ARDOUREL , Indrani CHAKRABORTY
IPC分类号： C07K16/28
摘要： The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.
-
公开(公告)号：US20170158757A1
公开(公告)日：2017-06-08
申请号：US15364612
申请日：2016-11-30
发明人： Mohan SRINIVASAN , Shrikant DESHPANDE , Qihong ZHAO , Huadong SUN , Ginger RAKESTRAW , Guodong CHEN , Richard Y. HUANG , Steven SHERIFF , Cristian RODRIGUEZ , John P. THROUP , Rose A. DIBELLA
CPC分类号： C07K16/24 , A61K9/0019 , A61K47/6845 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.
-
15.发明申请公开(公告)号：US20170137514A1
公开(公告)日：2017-05-18
申请号：US15296290
申请日：2016-10-18
发明人： Nils LONBERG , Mohan SRINIVASAN
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/2803 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K2039/507 , C07K16/18 , C07K16/28 , C07K16/2818 , C07K16/2827 , C07K16/3061 , C07K2317/14 , C07K2317/21 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
-
16.发明申请公开(公告)号：US20230050665A1
公开(公告)日：2023-02-16
申请号：US17364107
申请日：2021-06-30
发明人： Changyu WANG , Nils LONBERG , Alan J. KORMAN , Mark J. SELBY , Mohan SRINIVASAN , Karla HENNING , Michelle Minhua HAN , Guodong CHEN , Richard HUANG , Indrani CHAKRABORTY , Haichun HUANG , Susan WONG , Huiming LI
IPC分类号： C07K16/28 , A61K39/395 , G01N33/68 , G01N33/574
摘要： Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US20220281980A1
公开(公告)日：2022-09-08
申请号：US17582913
申请日：2022-01-24
发明人： Michelle Renee KUHNE , Alan J. KORMAN , Haichun HUANG , Yiming YIN , Robert F. GRAZIANO , Natalie A. BEZMAN , Pavel STROP , Richard Y. HUANG , Guodong CHEN , Mohan SRINIVASAN , Peter Sung Keun LEE , Gamze Ozlem CAMDERE
摘要： The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.
-
公开(公告)号：US20190284293A1
公开(公告)日：2019-09-19
申请号：US16081115
申请日：2017-03-03
发明人： Nils LONBERG , Alan J. KORMAN , Bryan C. BARNHART , Aaron P. YAMNIUK , Mohan SRINIVASAN , Karla A. HENNING , Ming LEI , Emanuela SEGA , Angela GOODENOUGH , Maria JURE-KUNKEL , Guodong CHEN , John S. SACK , Richard Y. HUANG , Martin J. CORBETT , Joseph E. MYERS, Jr. , Liang SCHWEIZER , Sandra V. HATCHER , Rachel A. ALTURA , Haichun HUANG , Pingping ZHANG , Edward J. HILT , Michael Nathan HEDRICK
摘要： Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD-1 antibody.
-
19.发明申请公开(公告)号：US20180339042A1
公开(公告)日：2018-11-29
申请号：US15776591
申请日：2016-11-17
发明人： Changyu WANG , Nils LONBERG , Alan J. KORMAN , Mark J. SELBY , Mohan SRINIVASAN , Karla A. HENNING , Michelle Minhua HAN , Guodong CHEN , Richard HUANG , Indrani CHAKRABORTY , Haichun HUANG , Susan Chien-Szu WONG , Huiming LI , Bryan C. BARNHART , Aaron P. YAMNIUK , Ming LEI , Liang SCHWEIZER , Sandra V. HATCHER , Arvind RAJPAL
IPC分类号： A61K39/395 , C07K16/28 , A61P35/04 , G01N33/68 , G01N33/574
摘要： Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US20180333502A1
公开(公告)日：2018-11-22
申请号：US15520954
申请日：2015-11-19
发明人： Nils LONBERG , Alan J. KORMAN , Mark J. SELBY , Bryan C. BARNHART , Aaron P. YAMNIUK , Mohan SRINIVASAN , Karla A. HENNING , Michelle Minhua HAN , Ming LEI , Liang SCHWEIZER , Sandra V. HATCHER , Arvind RAJPAL
IPC分类号： A61K47/68 , A61K39/395 , C07K16/30
CPC分类号： A61K47/6803 , A61K39/3955 , C07K16/00 , C07K16/2878 , C07K16/2896 , C07K16/30 , C07K2317/522 , C07K2317/524 , C07K2317/53 , C07K2317/71 , C07K2317/72 , C07K2317/75 , C07K2317/77 , C07K2317/92
摘要： Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.
-
-
-
-
-
-
-
-
-
搜索结果
33 条记录 (耗时 0.049 秒)
